S-8 EX-FILING FEES 0001367083 Fees to be Paid Fees to be Paid N/A 0001367083 1 2026-07-08 2026-07-08 0001367083 2 2026-07-08 2026-07-08 0001367083 2026-07-08 2026-07-08 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-8

SONOMA PHARMACEUTICALS, INC.

Table 1: Newly Registered Securities

                                       
Security Type   Security Class Title   Notes   Fee Calculation
Rule		   Amount Registered   Proposed Maximum Offering
Price Per Unit		   Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                       
Equity   Common Stock, par value $0.0001 per share, issued under the Sonoma Pharmaceuticals, Inc. 2016 Equity Incentive Plan   (1)   Other   143,924   $ 1.12   $ 161,194.88   0.0001381   $ 22.26
Equity   Common Stock, par value $0.0001 per share, issued under the Sonoma Pharmaceuticals, Inc. 2024 Equity Incentive Plan   (2)   Other   89,952   $ 1.12   $ 100,746.24   0.0001381   $ 13.91
                                       
Total Offering Amounts:   $ 261,941.12         36.17
Total Fee Offsets:               0.00
Net Fee Due:             $ 36.17

 

__________________________________________
Offering Note(s)

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended, the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend, recapitalization or any other similar transaction effected without receipt of consideration, which results in an increase in the number of the Registrant’s outstanding shares of Common Stock. In addition, pursuant to Rule 416(c) under the Securities Act, this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the Sonoma Pharmaceuticals, Inc. 2016 Equity Incentive Plan described herein.

Estimated solely for calculation of the registration fee pursuant to Rules 457(c) and (h)(1) under the Securities Act, based on the average of the high and low prices for the Registrant’s Common Stock on June 26, 2026, as reported on the Nasdaq Capital Market.

Represents shares of common stock that were added to the share authorized for issuance under the respective plan pursuant to “evergreen” provisions in the plan. Under these provisions, the number of shares authorized for issuance increased by 143,924 shares on April 1, 2026.

(2) Pursuant to Rule 416 under the Securities Act of 1933, as amended, the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend, recapitalization or any other similar transaction effected without receipt of consideration, which results in an increase in the number of the Registrant’s outstanding shares of Common Stock. In addition, pursuant to Rule 416(c) under the Securities Act, this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the Sonoma Pharmaceuticals, Inc. 2016 Equity Incentive Plan described herein.

Estimated solely for calculation of the registration fee pursuant to Rules 457(c) and (h)(1) under the Securities Act, based on the average of the high and low prices for the Registrant’s Common Stock on June 26, 2026, as reported on the Nasdaq Capital Market.

Represents shares of common stock that were added to the share authorized for issuance under the respective plan pursuant to “evergreen” provisions in the plan. Under these provisions, the number of shares authorized for issuance increased by 89,952 shares on April 1, 2026.